Login to Your Account

Biogen Paying $75M Up Front

Fibrosis Drugs Return Home In $562.5M Stromedix Buyout

By Catherine Shaffer
Staff Writer

Wednesday, February 15, 2012
A promising candidate for idiopathic pulmonary fibrosis forms the basis of an acquisition deal between Biogen Idec Inc. and Stromedix Inc., of Cambridge, Mass. Biogen will pay $75 million up front, and up to $487.5 million in milestones for the company, gaining Stromedix's humanized monoclonal antibody, STX-100.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription